Commercial Space Company Risk / Opportunity Ranking

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Camphouse after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Capsa AI after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CardNexus after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CeQur after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No reviewed sources-supported positive thesis is available. The reviewed sources explicitly says the summaries do not clearly connect CITIC Group to a qualifying space business.

Why now: There is no current catalyst. Despite 4,475 article IDs considered, the reviewed sources reports zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase2 rationale references article IDs: and: as context, but no were provided in the reviewed sources. Very large raw mention universe does not imply conviction or thesis attractiveness. Possible name/alias ambiguity is unresolved by the reviewed sources.

Thesis: No positive thesis is supported. The reviewed sources rationale says COMSAT appears only in the context of Intuitive Machines acquiring Goonhilly Earth Station/COMSAT, which is indirect and not sufficient for a company-specific opportunity view.

Why now: No 90-day article summaries or evidence were available for COMSAT in these reviewed sources, so there is no supported timing catalyst.

Caveats: Relations/context-only style mention should not be used as counterparty propagation evidence. Phase2 rationale references article ids: and: but no or summaries are provided in the reviewed sources. No direct evidence were available after recent evidence window.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale says EaglePicher is a key player in space batteries and that its systems were on NASA CLPS lunar lander missions, but no retained direct positive evidence or article summaries are available here.

Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set.

Thesis: The reviewed sources only indicates service/testing relevance in a Sidus-related context, and it contains no retained direct positive evidence with inside the recent evidence window, so there is no supported opportunity thesis.

Why now: Why now is absent because only 2 articles were considered and none survived the 90-day filter; there is no current evidence basis for a 1 year+ directional call.

Caveats: Coverage is extremely sparse. The only described relation is context/service oriented and relations are context-only unless policy-gated. No post-cutoff evidence available.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale references IHI benefiting from ICEYE SAR satellites and planning multi-sensor integration, but no retained direct evidence or article summaries are present here.

Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available.

Thesis: No direct positive evidence is available, and the reviewed sources say the included summaries do not clearly establish what Island Green Capital is.

Why now: No timing-based catalyst is supported because no post-recent evidence window evidence were available.

Caveats: Phase2 rationale references article IDs: and: but no were provided in the reviewed sources. Reviewed evidence states summaries were about Molten Ventures and Isar Aerospace rather than clearly about Island Green Capital. Context-only mentions cannot support propagation.

Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window.

Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window.

Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale describes air-launch and testing platform exposure, but no retained direct positive evidence or article summaries are provided here.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count.

Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale notes a letter of intent related to debris removal services, but no direct retained evidence row or article summary is provided in these reviewed sources.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis.

Thesis: No supported positive thesis. The reviewed sources say SWISSto12 is only mentioned in passing in an article about SpaceLocker, which is provisional single-article context and not company-specific evidence, unavailable in reviewed sources).

Why now: There is no identifiable catalyst because the reviewed sources provide only a passing mention and no direct event or fact evidence.

Caveats: No current evidence is provided for. Support level is provisional single-article context only. No evidence available after recent evidence window.

Thesis: No positive thesis is supported. Veact appears only via a broad funding roundup and is not linked to a space-specific category in the reviewed sources.

Why now: No why-now catalyst is supported because the reviewed sources contain no post-recent evidence window evidence.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. A broad funding roundup is not enough to establish thesis direction. Coverage data shows articles after recent evidence window = 0.

Thesis: No direct positive evidence is available. The reviewed sources only says Volteum surfaced from a general funding roundup with no space-specific linkage.

Why now: No catalyst is supported in the reviewed sources due to zero post-recent evidence window evidence.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. Funding-roundup presence alone is not directional proof. Evidence strength remains minimal.

Thesis: No reviewed sources-supported positive thesis is available. Zaro is only listed in a general funding roundup with no direct linkage to a qualifying space thesis.

Why now: There is no current or durable catalyst supported by the reviewed sources because no evidence survived into the available post-recent evidence window set.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. General funding-roundup context is weaker than direct event or fact evidence. Coverage remains insufficient for a directional call.

Thesis: No positive thesis can be supported from the reviewed sources because there is no direct positive evidence available for Zone14 within the 90-day recent evidence window.

Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence.

Thesis: The reviewed sources includes no material negative evidence; the main risk is thin grounding because the conclusion relies on one cited contract-related article without available detail or corroboration.

Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details.

Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace.

Thesis: Risk is moderate because the reviewed sources explicitly says it lacks direct, specific evidence of rocket company operations or a funding/contract event for Agnikul itself in the included material, so the opportunity case is not adequately grounded.

Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence.

Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window.

Thesis: Current ranking risk is mostly uncertainty risk: without retained evidence inside the 90-day window, the reviewed sources does not establish whether the referenced programs are progressing, delayed, funded, or commercially material.

Why now: There is no retained 90-day evidence in these reviewed sources despite references to evidence in earlier processing. Recency-sensitive conclusions therefore cannot be made from the local reviewed sources.

Caveats: Membership rationale references older evidence but no article IDs are provided with accessible summaries in these reviewed sources body. No representative articles or retained evidence are included. Low score reflects evidence absence, not a negative business judgment.

Thesis: No material adverse evidence is provided, but the reviewed sources does not show contract economics, execution milestones, or customer traction, so commercialization risk remains.

Why now: The reviewed sources' membership rationale cites article: for the integration agreement and technical collaboration, but no article or direct evidence are included.

Caveats: Evidence is thin and article-level details are missing. Collaboration and integration agreements are weaker than revenue-bearing customer wins. Single-article support limits conviction.

Thesis: The reviewed sources also explicitly says it is unclear whether Arctus is a true space company versus an atmospheric UAV company. That category ambiguity weakens thesis durability for this specific ranking universe, and no adverse company-specific event is otherwise available.

Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts.

Thesis: The main risk is evidentiary opacity: no kept structured positive or negative rows are available after recent evidence window, so business-state, traction, and durability are uncertain.

Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use.

Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources.

Thesis: The evidence is mostly supporting article context rather than strong company-specific event extraction, so execution and conversion risk remain, but there is no direct adverse evidence available.

Why now: Recent dated context within the 90-day recent evidence window points to fresh financing and government program inclusion, both relevant for a 1 year+ horizon: Andromeda context on April 8, 2026 and funding context on June 19, 2026

Caveats: Evidence is mainly supporting article context, which is weaker than direct event/fact evidence. An older 2025 article about a 2027 transportation deal exists, but it is outside the recent evidence window and not used as current proof.

Thesis: There is no direct adverse evidence, but the ranking is constrained by zero retained evidence after recent evidence window and potential duplication concerns in the broader article set.

Why now: The current batch retains no representative articles or evidence within the 90-day recent evidence window for Astranis, so the reviewed sources does not provide a current dated catalyst despite the phase-2 rationale.

Caveats: No retained evidence after recent evidence window. Phase-2 rationale mentions duplicate article versions; duplicates would not be independent confirmation anyway.

Thesis: No material adverse evidence is available in the reviewed sources, so a negative thesis is unsupported.

Why now: The rationale references articles, and: but no corresponding available evidence remains available for direct scoring after recent evidence filtering.

Caveats: Lunar lander category fit does not equal thesis attractiveness. Coverage debug shows zero available evidence after recent evidence window. Without direct execution, funding, contract-conversion, or mission-status evidence, scores should remain conservative.

Thesis: The key risk is that the only described support is partner context, and the reviewed sources explicitly notes the relation row is context-only, leaving no strong basis for a company-specific positive or negative operating thesis.

Why now: There is no usable 'why now' beyond possible strategic relevance to optical communications. The reviewed sources provide no after-recent evidence window evidence to confirm current status.

Caveats: Phase-2 rationale references, but the reviewed sources does not include its or article summary. Relations marked context-only cannot be used as counterparty propagation evidence. Coverage debug shows zero evidence after recent evidence window.

Thesis: The risk is that technical demonstration does not confirm scalable commercial adoption, contracts, or follow-on funding, and none of those are evidenced in the kept reviewed sources rows.

Why now: The only support cited is article in the membership rationale. Because the company coverage report shows zero articles after recent evidence window and zero evidence after recent evidence window, there is no robust timing catalyst beyond the historical demonstration narrative.

Caveats: Single-article support only, and not available as active evidence. No direct evidence on customer conversion, regulatory adoption, or funding. Private-company visibility is limited in these reviewed sources.

Thesis: Risk is mostly uncertainty from minimal coverage: only one article was considered and zero evidence were available after recent evidence window, so durability, backlog, and execution status are unverified here.

Why now: Why now is weak because there is no surviving 90-day evidence row in the reviewed sources to establish recency or momentum.

Caveats: Only membership rationale is available; no citeable direct evidence with are provided. Single-article universe increases fragility of inference.

Thesis: No direct adverse evidence is provided in the reviewed sources; main risk is limited visibility into commercialization and scale from the single referenced article.

Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale.

Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here.

Thesis: Risk is primarily execution and verification uncertainty because the reviewed sources have zero available evidence after recent evidence window, so no current milestone, financing, or contract confirmation is available.

Why now: Why now is only moderate in theory because propulsion/platform partnerships can matter over a 1-year-plus horizon, but these reviewed sources does not provide recency-anchored evidence after recent evidence window.

Caveats: No direct evidence with available for citation. Technology differentiation is only inferred from membership rationale and is not independently corroborated in available evidence.

Thesis: The main risk is evidence quality: the reviewed sources itself says the evidence is mostly partnership context and lacks direct company-specific operating detail, which weakens any durable 1 year+ thesis. There is still no material adverse event available after recent evidence window.

Why now: No near-term or durable catalyst can be established from retained evidence because coverage debug shows zero article IDs and zero evidence after recent evidence window.

Caveats: No are provided for the cited support articles in the reviewed sources. The reviewed sources explicitly characterizes the evidence as mostly partnership context rather than direct operating detail. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Source-specific risk is low because there is no available direct adverse evidence tied to Boeing's space thesis in this screen. The main offset is that the contract contributes to a long-cycle program with delivery beginning in 2031, so near-term financial realization is likely gradual rather than immediate, but that is not a negative event

Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance

Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031.

Thesis: Risk is modest due to lack of current corroborating evidence rather than any adverse development. The reviewed sources contain no direct negative evidence.

Why now: Why now is weak because no representative article or direct evidence survives in the ranking fields after recent evidence window; only membership rationale references without surfaced article content.

Caveats: No direct within the recent evidence window evidence is available in ranking fields. Membership rationale alone is weaker than surfaced company-specific event evidence. No negative thesis is supportable from the reviewed sources.

Thesis: The same rationale says there is little direct company-specific detail beyond inclusion in that group. Without available direct evidence after recent evidence window, the main risk is thesis fragility and inability to verify the claimed IPO/pre-IPO progression.

Why now: There is no verified current catalyst in retained evidence. IPO/pre-IPO framing could matter on a 1 year+ horizon, but recency and milestone state cannot be confirmed here because no dated evidence are available after recent evidence window.

Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. IPO/pre-IPO mention is only in reviewed sources rationale, not in retained direct evidence.

Thesis: Casimir carries above-peer evidence risk in this screen because the sole cited support is described in the phase2 rationale as blog commentary, and the business fit to the target cohort is explicitly questioned. That weak grounding raises the risk of over-interpreting the financing mention.

Why now: There is no available article summary or evidence row after recent evidence window, so the only 'why now' is the uncitable phase2 statement about a seed round referenced by article id: without.

Caveats: The reviewed sources itself says the support article is blog commentary, weakening source quality. No citable or summary is provided for the referenced article id No evidence were available after recent evidence window in the served reviewed sources.

Thesis: Risk remains moderate because the evidence is still supporting article context rather than direct company disclosures about backlog, margins, or contracted demand, and no negative evidence is available. Execution risk remains around converting first-launch and funding momentum into durable commercial scale.

Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026.

Caveats: Evidence is external article context, not a direct company filing or contract announcement.